524572 PHARMAID

Pharmaids Pharmaceuticals Share Price

 

 

Start SIP in PHARMAID

Start SIP

Performance

  • Low
  • ₹48
  • High
  • ₹54
  • 52 Week Low
  • ₹42
  • 52 Week High
  • ₹85
  • Open Price₹54
  • Previous Close₹52
  • Volume2,159

Investment Returns

  • Over 1 Month + 4.75%
  • Over 3 Month -18.22%
  • Over 6 Month -13.97%
  • Over 1 Year -16.8%

Smart Investing Starts Here Start SIP with Pharmaids Pharmaceuticals for Steady Growth!

Invest Now

Pharmaids Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -13.4
  • PEG Ratio
  • 1.3
  • Market Cap Cr
  • 178
  • P/B Ratio
  • Average True Range
  • 3.91
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.72
  • RSI
  • 54.48
  • MFI
  • 72.49

Pharmaids Pharmaceuticals Financials

Pharmaids Pharmaceuticals Technicals

EMA & SMA

Current Price
₹50.50
-1.03 (-2%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹48.32
  • 50 Day
  • ₹50.33
  • 100 Day
  • ₹53.82
  • 200 Day
  • ₹56.77

Resistance and Support

50.57 Pivot Speed
  • R3 59.23
  • R2 56.37
  • R1 53.43
  • S1 47.63
  • S2 44.77
  • S3 41.83

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Pharmaids Pharms. has an operating revenue of Rs. 24.75 Cr. on a trailing 12-month basis. An annual revenue growth of 22% is outstanding, Pre-tax margin of -89% needs improvement, ROE of -18% is poor and needs improvement. The company has a debt to equity of 51%, which is bit higher. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 10 which is a POOR score indicating inconsistency in earnings, a RS Rating of 28 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 66 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Pharmaids Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-11 Quarterly Results
2025-08-07 Quarterly Results
2025-05-23 Audited Results
2025-02-12 Quarterly Results
2024-11-13 Quarterly Results

Pharmaids Pharmaceuticals F&O

Pharmaids Pharmaceuticals Shareholding Pattern

32.99%
47.02%
19.99%

Pharmaids Pharmaceuticals FAQs

Pharmaids Pharmaceuticals share price is ₹50 As on 07 December, 2025 | 05:21

The Market Cap of Pharmaids Pharmaceuticals is ₹178.1 Cr As on 07 December, 2025 | 05:21

The P/E ratio of Pharmaids Pharmaceuticals is -13.4 As on 07 December, 2025 | 05:21

The PB ratio of Pharmaids Pharmaceuticals is 2.7 As on 07 December, 2025 | 05:21

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23